S8 Additional file. Metasummary tables.

Table 1. Summary of all barrier themes that emerged for both preventive therapies, identified in forty studies included in this review.

Health system component Emerging barrier themes	No. of articles	Supporting articles
Patient & community related barriers		
Adverse reactions (side effects)	18	[1-18]
Lacking financial and organisational feasibility	14	[1, 2, 4, 6, 8, 10, 12, 13, 15, 19-23]
Knowledge gaps & misperceptions	14	[2, 4, 10-14, 17-22, 24]
Patients‘ lacking motivation	12	[2, 4, 6, 11-15, 18, 19, 21, 22]
Forgetfulness	4	[2, 6, 9, 23]
Patients' HIV denial, religion & competing medicinal approaches	7	[2, 3, 10, 13, 15, 16, 19]
Stigma & fear of rejection/ discrimination	11	[2, 3, 8, 10, 13, 15, 16, 19, 20, 22, 23]
Influence of relatives and friends	8	[2, 3, 8, 11-13, 15, 19]
*Socio-demographic, lifestyle and clinical factors	10	[1, 2, 7, 8, 10, 12, 16, 18, 25, 26]
*Concerns about the efficacy of CPT	2	[9, 11]
Health provider related barriers		
Shortage of health providers	12	[1, 3, 7, 12, 14, 17, 18, 22, 24, 27-29]
Knowledge- and training gaps	12	[1, 3, 7, 12, 18, 19, 21, 22, 24, 28, 30, 31]
*Attitudes, beliefs & fear to induce INH resistance	10	[5, 7, 12, 14, 17-19, 21, 24, 28]
*Provider-patient communication	3	[6, 20, 24]
Clinical information related barriers		
Inaccurate recording and lack of integration of health records	9	[3, 7, 13, 17, 22, 24, 28, 30, 32]
Ineffective monitoring, evaluation & surveillance	4	[7, 17, 22, 29]
Pharmaceutical management related barriers		
Stock-outs/ Shortages of PT’s	16	[3, 4, 12, 14, 15, 17, 18, 20, 22-24, 26, 28, 29, 33, 34]
Lack of pharmaceutical personnel	2	[3, 29]
*Lack of written instructions	1	[3]
Service delivery related barriers		
Sub-optimal service delivery	14	[1, 4, 12, 14, 15, 18-20, 22, 24, 27, 29, 30, 32]
Inadequate facility infrastructure	3	[4, 22, 29]
Poor integration of preventive therapy-related services	10	[1, 3, 7, 18, 20-22, 29, 30, 33]
Patient loss to follow-up	7	[2, 12, 13, 17, 25, 29, 30]
*Ruling out TB disease	15	[1, 5, 7, 12, 14, 17, 18, 20-22, 24, 28, 35-37]
*Investigation of TB suspects	8	[7, 14, 17, 21, 22, 28, 36, 37]
Health system financing related barriers		
Health system funding issues	4	[4, 7, 29, 35]
Vertical funding	3	[7, 22, 29]
Leadership & governance related barriers		
Issues regarding policies & guidelines	8	[4, 7, 17, 18, 21, 22, 24, 35]
Lacking leadership and coordination	6	[1, 7, 18, 20, 22, 30]
Lacking top-down policy support and management issues	4	[18, 20, 22, 24]
Inadequate planning	2	[7, 22]
Lacking engagement of stakeholders	3	[7, 18, 22]

Total number of themes identified (N= 32), Intervention specific themes (n= 7). The asterisk (*) is used to highlight intervention-specific themes.
CPT - cotrimoxazole preventive therapy; IPT – isoniazid preventive therapy, PT - preventive therapy; INH – isoniazid..

S8 Additional file. Metasummary tables.

Table 2. Summary of barrier themes that emerged for cotrimoxazole preventive therapy.

Health system component Emerging barrier themes	No. of articles	Relevant articles
Patient & community related barriers	7	[3, 4, 7, 9, 11, 15, 22]
Adverse reactions (side effects)	6	[3, 4, 7, 9, 11, 15]
Lacking financial and organisational feasibility	3	[4, 15, 22]
Knowledge gaps & misperceptions	2	[4, 11]
Patients‘ lacking motivation	4	[4, 11, 15, 22]
Forgetfulness	1	[9]
Patients' HIV denial, religion & competing medicinal approaches	2	[3, 15]
Stigma & fear of rejection/ discrimination	3	[3, 15, 22]
Influence of relatives and friends	3	[3, 11, 15]
*Concerns about the efficacy of CPT	2	[9, 11]
Health provider related barriers	4	[3, 22, 30, 31]
Shortage of health providers	1	[3]
Knowledge and training gaps	4	[3, 22, 30, 31]
Clinical information related barriers	5	[3, 7, 22, 30, 32]
Inaccurate recording and lack of integration of health records	5	[3, 7, 22, 30, 32]
Ineffective monitoring, evaluation & surveillance	2	[7, 22]
Pharmaceutical management related barriers	6	[3, 4, 7, 15, 22, 33]
Stock-outs/ Shortages of PT’s	6	[3, 4, 7, 15, 22, 33]
Lack of pharmaceutical personnel	1	[3]
*Lack of written instructions	1	[3]
Service delivery related barriers	8	[3, 4, 7, 15, 22, 30, 32, 33]
Sub-optimal service delivery	5	[4, 15, 22, 30, 32]
Inadequate facility infrastructure	2	[4, 22]
Poor integration of preventive therapy-related services	5	[3, 7, 22, 30, 33]
Patient loss to follow-up	1	[30]
Health system financing related barriers	3	[4, 7, 22]
Health system funding issues	2	[7, 22]
Vertical funding	2	[4, 7]
Leadership & governance related barriers	3	[4, 22, 30]
Issues regarding policies & guidelines	2	[4, 22]
Lacking leadership & coordination	2	[22, 30]
Lacking top-down policy support & management issues	1	[22]
Inadequate planning	1	[22]
Lacking engagement of stakeholders	1	[22]

Barrier themes presented in this table emerged from eleven peer-reviewed articles identified with barriers to CPT.
Total number of themes identified (N= 27), Intervention specific themes (n= 2). The asterisk (*) is used to highlight intervention-specific themes.
CPT - cotrimoxazole preventive therapy; PT - preventive therapy.

S8 Additional file. Metasummary tables.

Table 3. Summary of barrier themes that emerged for isoniazid preventive therapy.

Health system component Emerging barrier themes	No. of articles	Relevant articles
Patient & community related barriers	21	[1, 2, 5-8, 10, 12-14, 16-26]
Adverse reactions (side effects)	13	[1, 2, 5-8, 10, 12-14, 16-18]
Lacking financial and organisational feasibility	12	[1, 2, 6, 8, 10, 12, 13, 19-23]
Knowledge gaps & misperceptions	12	[2, 10, 12-14, 17-22, 24]
Patients‘ lacking motivation	9	[2, 6, 11-14, 18, 19, 21]
Forgetfulness	3	[2, 6, 23]
Patients' HIV denial, religion & competing medicinal approaches	5	[2, 10, 13, 16, 19]
Stigma & fear of rejection/ discrimination	9	[2, 8, 10, 13, 16, 19, 20, 22, 23]
Influence of relatives and friends	5	[2, 8, 12, 13, 19]
*Socio-demographic, lifestyle and clinical factors	10	[1, 2, 7, 8, 10, 12, 16, 18, 25, 26]
Health provider related barriers	16	[1, 5-7, 12, 14, 17-22, 24, 27-29]
Shortage of health providers	11	[1, 7, 12, 14, 17, 18, 22, 24, 27-29]
Knowledge and training gaps	9	[1, 7, 12, 18, 19, 21, 22, 24, 28]
*Attitudes, beliefs & fear to induce INH resistance	10	[5, 7, 12, 14, 17-19, 21, 24, 28]
*Provider-patient communication	3	[6, 20, 24]
Clinical information related barriers	7	[7, 13, 17, 22, 24, 28, 29]
Inaccurate recording and lack of integration of health records	6	[7, 13, 17, 22, 24, 28]
Ineffective monitoring, evaluation & surveillance	4	[7, 17, 22, 29]
Pharmaceutical management related barriers	10	[12, 14, 17, 18, 20, 23, 24, 28, 29, 34]
Stock-outs/ Shortages of PT’s	10	[12, 14, 17, 18, 20, 23, 24, 28, 29, 34]
Lack of pharmaceutical personnel	1	[29]
Service delivery related barriers	21	[1, 2, 5, 7, 12-14, 17-22, 24, 25, 27-29, 35-37]
Sub-optimal service delivery	10	[1, 12, 14, 18-20, 22, 24, 27, 29]
Inadequate facility infrastructure	1	[29]
Poor integration of preventive therapy-related services	7	[1, 7, 18, 20-22, 29]
Patient loss to follow-up	6	[2, 12, 13, 17, 25, 29]
*Ruling out TB disease	15	[1, 5, 7, 12, 14, 17, 18, 20-22, 24, 28, 35-37]
*Investigation of TB suspects	8	[7, 14, 17, 21, 22, 28, 36, 37]
Health system financing related barriers	4	[7, 22, 29, 35]
Health system funding issues	3	[7, 29, 35]
Vertical funding	3	[7, 22, 29]
Leadership & governance related barriers	9	[1, 7, 17, 18, 20-22, 24, 35]
Issues regarding policies & guidelines	7	[7, 17, 18, 21, 22, 24, 35]
Lacking leadership & coordination	5	[1, 7, 18, 20, 22]
Lacking top-down policy support & management issues	4	[18, 20, 22, 24]
Inadequate planning	2	[7, 22]
Lacking engagement of stakeholders	3	[7, 18, 22]

Barrier themes presented in this table emerged from twenty-eight peer-reviewed articles identified with barriers to IPT.
Total number of themes identified (N= 30), Intervention specific themes (n= 5). The asterisk (*) is used to highlight intervention-specific themes.
IPT - isoniazid preventive therapy; INH - isoniazid.

S8 Additional file. Metasummary tables.

Table 4. Relative magnitude of health system components identified as the source of barriers to cotrimoxazole preventive therapy.

Peer-reviewed articles reporting barriers to CPT (N= 11) / Health system component from which barriers arose	Chan (2014)	Horwood (2010)	Kamuhabwa (2015)	Kamuhabwa(2016)	Lougwagie (2012)	Mugomeri (2018)*	Mwambete (2013)	Naikoba (2017)	Okot-Chono (2009)*	Okwera (2015)	Sibanda (2015)	Frequency	Effect size [%]
Patient & community			X	X		X	X		X	X	X	7/11	64
Health providers		X		X				X	X			4/11	36
Clinical information		X		X	X	X			X			5/11	45
Pharmaceutical management	X		X	X		X			X		X	6/11	**55**
Service delivery	X	X	X	X	X	X			X		X	8/11	**73**
Health system financing			X			X			X			3/11	27
Leadership & governance		X	X						X			3/11	27

*Two studies reported barriers to both preventive therapies (Okot-Chono (2009), Mugomeri (2018)). CPT - cotrimoxazole preventive therapy.
Out of the 14 peer-reviewed articles identified for CPT, three articles (Luyirika, (2013), Chang (2015), Ansa (2014)) only addressed facilitators for CPT, and where therefore excluded from metasummary.

Table 5. Relative magnitude of health system components identified as the source of barriers to isoniazid preventive therapy.

Peer-reviewed articles reporting barriers to IPT (N= 28) / Health system component from which barriers arose	Adepoju (2020)	Aisu (1995)	Catalani (2014)	Durovni (2010)	Faust (2020)	Gust (2011)	Huerga (2016)	Jacobson (2017)	Jarrett (2019)	Khan (2014)	Lai (2019)	Lester (2010)	Little (2018)	McRobie (2017)	Meribe (2020)	Mindachew (2011)	Mugomeri (2018)*	Mugomeri (2019)	Munseri (2008)	Ngamvithayapong (1997)	Okot-Chono (2009)*	Reddy (2020)	Rowe (2005)	Selehelo (2019)	Szakacs (2006)	Tram (2020)	Van Ginderdeuren (2019)	Wambiya (2018)	Frequency	Effect size [%]
Patient & community		X		X		X		X	X		X	X	X			X	X	X	X	X	X	X	X	X	X	X	X	X	21/28	**75**
Health providers	X	X	X	X				X	X		X	X		X		X	X				X	X		X			X	X	16/28	**57**
Clinical information			X						X					X			X				X		X				X		7/28	33
Pharmaceutical management			X					X	X					X	X							X		X	X		X	X	10/28	36
Service delivery	X	X	X	X	X	X	X	X	X	X	X	X	X	X			X				X	X	X	X			X	X	21/28	**75**
Health system financing					X									X			X				X								4/28	4
Leadership & governance				X	X			X	X			X					X				X						X	X	9/28	32

All twenty-eight articles identified for IPT were included for metasummary. *Two studies reported barriers to both preventive therapies (Okot-Chono (2009), Mugomeri (2018)). IPT - isoniazid preventive therapy.

S8 Additional file. Metasummary tables.

References

1. Durovni, B., et al., *The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.* AIDS (London, England), 2010. **24**(Suppl 5): p. S49.
2. Gust, D.A., et al., *Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana.* PLoS One, 2011. **6**(4): p. e18435.
3. Kamuhabwa, A.A., R. Gordian, and R.F. Mutagonda, *Implementation of co-trimoxazole preventive therapy policy for malaria in HIV-infected pregnant women in the public health facilities in Tanzania.* Drug Healthc Patient Saf, 2016. **8**: p. 91-100.
4. Kamuhabwa, A.A.R. and V. Manyanga, *Challenges facing effective implementation of cotrimoxazole prophylaxis in children born to HIV-infected mothers in the public health facilities.* Drug Healthcare and Patient Safety, 2015. **7**: p. 147-156.
5. Lai, J., et al., *Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia.* Int J Tuberc Lung Dis, 2019. **23**(3): p. 371-377.
6. Mindachew, M., et al., *Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.* BMC public health, 2011. **11**(1): p. 916.
7. Mugomeri, E., D. Olivier, and W.M. Van Den Heever, *Health system challenges affecting the implementation of isoniazid preventive therapy in people living with HIV in Lesotho.* HIV and AIDS Review, 2018. **17**(4): p. 299-307.
8. Munseri, P., et al., *Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.* The International Journal of Tuberculosis and Lung Disease, 2008. **12**(9): p. 1037-1041.
9. Mwambete, K.D. and A.A. Kamuhabwa, *Resistance of commensal intestinal Escherichia coli and other enterics to co-trimoxazole and commonly used antibiotics in HIV/AIDS patients.* Clinical Microbiology: Open Access, 2013.
10. Ngamvithayapong, J., et al., *Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand.* Aids, 1997. **11**(1): p. 107-112.
11. Okwera, A., et al., *Level of understanding of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative analysis.* Afr Health Sci, 2015. **15**(1): p. 49-57.
12. Reddy, M.M., et al., *To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.* Glob Health Action, 2020. **13**(1): p. 1704540.
13. Rowe, K.A., et al., *Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?* Int J Tuberc Lung Dis, 2005. **9**(3): p. 263-9.
14. Selehelo, K., L. Makhado, and K.A. Madiba, *Provision of Isoniazid Preventive Therapy: The Experiences of People Living with HIV.* African Journal of Nursing and Midwifery, 2019. **21**(2).
15. Sibanda, E.L., et al., *Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe.* BMC Public Health, 2015. **15**: p. 784.
16. Tram, K.H., et al., *Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.* Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv, 2019. **32**(1): p. 119-127.
17. Van Ginderdeuren, E., et al., *Health system barriers to implementation of TB preventive strategies in South African primary care facilities.* PLoS One, 2019. **14**(2): p. e0212035.
18. Wambiya, E.O.A., et al., *Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.* BMJ Open, 2018. **8**(12): p. e024286.
19. Aisu, T., et al., *Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.* AIDS (London, England), 1995. **9**(3): p. 267-273.
20. Jacobson, K.B., et al., *"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.* Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv, 2017. **29**(7): p. 936-942.
21. Lester, R., et al., *Barriers to implementation of isoniazid preventive therapy in HIV clinics: A qualitative study.* AIDS, 2010. **24**(SUPPL. 5): p. S45-S48.
22. Okot-Chono, R., et al., *Health system barriers affecting the implementation of collaborative TB-HIV services in Uganda.* The international journal of tuberculosis and lung disease, 2009. **13**(8): p. 955-961.

23. Szakacs, T.A., et al., *Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.* BMC infectious diseases, 2006. **6**(1): p. 97.
24. Jarrett, B.A., et al., *Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics.* Aids and Behavior, 2019. **24**(4): p. 1106-1117.
25. Little, K.M., et al., *Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.* Int J Tuberc Lung Dis, 2018. **22**(4): p. 371-377.
26. Mugomeri, E., D. Olivier, and W.M.J. van den Heever, *Tracking the rate of initiation and retention on isoniazid preventive therapy in a high human immunodeficiency virus and tuberculosis burden setting of Lesotho.* Southern African Journal of Infectious Diseases, 2019. **34**(1).
27. Adepoju, A.V., et al., *Implementation of Isoniazid Preventive Therapy among People Living with HIV in Northwestern Nigeria: Completion Rate and Predictive Factors.* J Glob Infect Dis, 2020. **12**(2): p. 105-111.
28. Catalani, C., et al., *A Clinical Decision Support System for Integrating Tuberculosis and HIV Care in Kenya: A Human-Centered Design Approach.* Plos One, 2014. **9**(8).
29. McRobie, E., et al., *HIV policy implementation in two health and demographic surveillance sites in Uganda: Findings from a national policy review, health facility surveys and key informant interviews.* Implementation Science, 2017. **12**(1).
30. Horwood, C., et al., *Prevention of mother to child transmission of HIV (PMTCT) programme in KwaZulu-Natal, South Africa: an evaluation of PMTCT implementation and integration into routine maternal, child and women's health services.* Trop Med Int Health, 2010. **15**(9): p. 992-9.
31. Naikoba, S., et al., *Improved HIV and TB Knowledge and Competence among Mid-level Providers in a Cluster-Randomized Trial of One-on-One Mentorship for Task Shifting.* Journal of Acquired Immune Deficiency Syndromes, 2017. **75**(5): p. e120-e127.
32. Louwagie, G., et al., *Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care.* International Journal of Tuberculosis and Lung Disease, 2012. **16**(8): p. 1052-1058.
33. Chan, A.K., et al., *The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe.* Bmc Health Services Research, 2014. **14**.
34. Meribe, S.C., et al., *Sustaining tuberculosis preventive therapy scale-up through direct supportive supervision.* Public Health Action, 2020. **10**(2): p. 60-63.
35. Faust, L., et al., *How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers.* Health Sci Rep, 2020. **3**(2): p. e158.
36. Huerga, H., et al., *Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.* J Acquir Immune Defic Syndr, 2016. **71**(4): p. e89-95.
37. Khan, F.A., et al., *Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped.* Aids, 2014. **28**(10): p. 1463-1472.